Webinar presenters Kyle C. Strickland, MD, PhD, Director of Medical Affairs, Labcorp, and Tricia Numan, MD, Gynecologic Pathologist and Director of the Women’s Health Initiative at Roswell Park Comprehensive Cancer Center, discuss the biology and clinical significance of homologous recombination deficiency (HRD) in ovarian cancer.
This on-demand webinar was originally broadcast on April 2, 2026.
What will this webinar empower you to do?
• Explore Labcorp’s latest enhancement to OmniSeq® INSIGHT utilizing integrated HRD assessment with Illumina’s TSO500 HRD workflow. We’ll review how genomic scars—including loss of heterozygosity, telomeric allelic imbalance and large‑scale state transitions—define the HRD phenotype and help predict response to platinum therapy and PARP inhibitors.
• Examine tumors that lack HRD, focusing on the emerging HR‑proficient/RB1‑high molecular subtype characterized by poor outcomes, high aneuploidy and distinct transcriptional signaling.
• Understand how this data underscores the importance of expanded genomic profiling for both HR‑deficient and HR‑proficient cancers, demonstrating how OmniSeq INSIGHT provides a comprehensive molecular profile that supports precision oncology and ongoing biomarker‑
driven research in gynecologic malignancies.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Labcorp.